New research identifies effective treatment for common gynecological problem

New research from the Los Angeles Biomedical Research Institute (LA BioMed) found a progestogen-only treatment halted bleeding in women suffering from extremely heavy periods, according to the study published online by the American Journal of Obstetrics and Gynecology.

"Excessive uterine bleeding is a common problem we see in gynecological practices and emergency rooms. It can interfere with women's daily activities and put them at risk for anemia and other more serious caused by ," said Anita L. Nelson, MD, a LA BioMed lead investigator and corresponding author of the study. "Until now, there has been no -approved products for short-term treatment of this condition. Based on our study, we conclude that this new progestogen-only treatment is effective in stopping acute abnormal uterine bleeding."

Within five days of receiving the , bleeding had ceased in 44 of the 48 women in the study, and the other four were only experiencing spotting. The mean time to bleeding cessation was 2.6 days, leading the researchers to conclude the progestogen-only treatment was an effective short-term therapy for acute abnormal uterine bleeding.

In the pilot study, the patients received a 150-milligram injection of Depomedroxyprogesterone acetate (DMPA) and then were given acetate (MPA) 20 milligram pills that were to be taken orally every eight hours for three days.

"This is the largest prospective study to date to measure the effectiveness of a proposed for excessive uterine bleeding," said Dr. Nelson. "The women in the study experienced excellent success with this relatively low dose progestogen-only therapy. This therapy also has the potential for offering longer-term protection than prior therapies."

The therapy was shown to halt bleeding rapidly while appropriate testing could identify the underlying causes of the excessive bleeding. As such, Dr. Nelson said the therapy provides a "temporary bridge to long-term targeted therapies." She also said the regimen had "good compliance, few side effects and high patient satisfaction." In addition, she said it was an attractive treatment option for women with contraindications to estrogen, those who need more prolonged therapy and those who may have difficulty with daily pill administration.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

'Science' features advances in preterm birth

Aug 15, 2014

The Aug. 15 edition of the journal Science features a major article about the most important problem in obstetrics: preterm labor. The article, "Preterm labor: one syndrome, many causes," delivers a powerf ...

Treatment does not prevent pre-eclampsia, pregnancy loss

Aug 13, 2014

International research involving the University of Adelaide has shown an anti-blood clotting treatment that has been used for more than 20 years to prevent a range of serious pregnancy complications is not ...

User comments